梅花生物
(600873)
| 流通市值：222.10亿 | | | 总市值：222.10亿 |
| 流通股本：28.04亿 | | | 总股本：28.04亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 12,235,095,339.54 | 5,985,631,650.28 | 24,208,675,106.7 | 18,215,447,345 |
| 营业收入 | 12,235,095,339.54 | 5,985,631,650.28 | 24,208,675,106.7 | 18,215,447,345 |
| 二、营业总成本 | 11,604,845,391.33 | 5,882,482,412.56 | 21,603,821,463.14 | 15,834,727,996.42 |
| 营业成本 | 10,653,093,825.19 | 5,415,277,356.94 | 19,609,399,374.08 | 14,342,185,989.36 |
| 税金及附加 | 109,283,193.92 | 55,628,460.07 | 246,746,460.77 | 188,004,044.32 |
| 销售费用 | 176,534,959.81 | 81,998,236.22 | 362,971,160.8 | 273,352,514.87 |
| 管理费用 | 424,785,142.26 | 209,702,435.56 | 991,548,421.96 | 749,123,230.1 |
| 研发费用 | 187,548,443.45 | 94,329,806.93 | 389,151,493.26 | 296,016,607.21 |
| 财务费用 | 53,599,826.7 | 25,546,116.84 | 4,004,552.27 | -13,954,389.44 |
| 其中:利息费用 | 20,836,234.31 | 11,828,031.97 | 52,269,326.61 | 40,273,509.95 |
| 其中:利息收入 | 20,897,261.18 | 10,981,912.4 | 59,618,168.61 | 42,750,808.43 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 21,336,805.37 | 3,921,785.19 | 32,838,480.38 | 25,374,357.22 |
| 加:投资收益 | 57,912,082.18 | 11,986,698.51 | 57,847,648.05 | 42,049,338.03 |
| 资产处置收益 | 10,663,776.45 | 918,356.14 | 834,727.21 | 589,156.66 |
| 资产减值损失(新) | -29,797,994.41 | 66,100.94 | -36,034,934.84 | -9,348,180.66 |
| 信用减值损失(新) | -4,068,410.89 | 2,063,208.02 | 10,379,492.7 | 136,864.37 |
| 其他收益 | 132,481,579.46 | 17,168,441.37 | 238,343,273.35 | 219,409,461.61 |
| 四、营业利润 | 818,777,786.37 | 139,273,827.89 | 2,909,062,330.41 | 2,658,930,345.81 |
| 加:营业外收入 | 22,347,099.23 | 17,731,079.86 | 870,774,265.2 | 786,644,604.51 |
| 减:营业外支出 | 10,722,111.16 | 2,688,115.04 | 50,136,606.69 | 3,070,420.99 |
| 五、利润总额 | 830,402,774.44 | 154,316,792.71 | 3,729,699,988.92 | 3,442,504,529.33 |
| 减:所得税费用 | 168,540,068.21 | 36,395,828.64 | 448,820,076.82 | 417,412,174.28 |
| 六、净利润 | 661,862,706.23 | 117,920,964.07 | 3,280,879,912.1 | 3,025,092,355.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 661,862,706.23 | 117,920,964.07 | 3,280,879,912.1 | 3,025,092,355.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 661,862,706.23 | 117,920,964.07 | 3,280,879,912.1 | 3,025,092,355.05 |
| 扣除非经常损益后的净利润 | 451,313,771.78 | 80,256,263.63 | 2,205,459,805.05 | 2,019,475,140.77 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.24 | 0.04 | 1.17 | 1.06 |
| (二)稀释每股收益 | 0.24 | 0.04 | 1.17 | 1.06 |
| 八、其他综合收益 | -99,766,392.99 | -49,472,357.85 | -104,215,210.75 | -80,102,163.16 |
| 归属于母公司股东的其他综合收益 | -99,766,392.99 | -49,472,357.85 | -104,215,210.75 | -80,102,163.16 |
| 九、综合收益总额 | 562,096,313.24 | 68,448,606.22 | 3,176,664,701.35 | 2,944,990,191.89 |
| 归属于母公司股东的综合收益总额 | 562,096,313.24 | 68,448,606.22 | 3,176,664,701.35 | 2,944,990,191.89 |
| 公告日期 | 2026-08-15 | 2026-04-22 | 2026-04-22 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |